Pyxis Oncology (PYXS) News Today $1.28 -0.08 (-5.88%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.29 +0.01 (+0.78%) As of 02/21/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Pyxis Oncology initiates new PYX-201 trial, initiates cohort expansionsFebruary 4, 2025 | markets.businessinsider.comPyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy TrialFebruary 4, 2025 | globenewswire.comPyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of "Moderate Buy" from AnalystsPyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The aFebruary 1, 2025 | marketbeat.comPyxis Oncology stock outlook adjusted with focus on ADC program and cost managementDecember 26, 2024 | uk.investing.comPyxis Oncology price target lowered to $8 from $10 at RBC CapitalDecember 21, 2024 | markets.businessinsider.comStrategic Focus on PYX-201 Drives Positive Buy Rating for Pyxis OncologyDecember 20, 2024 | markets.businessinsider.comPyxis Oncology’s Strategic Focus on PYX-201 and Collaboration with Merck Drives Buy RatingDecember 20, 2024 | markets.businessinsider.comPyxis Oncology's (PYXS) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $5.00 price objective (down previously from $7.00) on shares of Pyxis Oncology in a report on Friday.December 20, 2024 | marketbeat.comRoyal Bank of Canada Reaffirms Outperform Rating for Pyxis Oncology (NASDAQ:PYXS)Royal Bank of Canada reaffirmed an "outperform" rating and issued a $8.00 price objective (down previously from $10.00) on shares of Pyxis Oncology in a research note on Friday.December 20, 2024 | marketbeat.comPyxis Oncology to prioritize PYX-201, suspends investment in PYX-106December 20, 2024 | markets.businessinsider.comPyxis Oncology to Focus on PYX-201, Suspends PYX-106 ProgramDecember 19, 2024 | marketwatch.comPyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201December 19, 2024 | globenewswire.comPyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and eight have issued a bDecember 13, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Invests $1.41 Million in Pyxis Oncology, Inc. (NASDAQ:PYXS)Jacobs Levy Equity Management Inc. purchased a new stake in Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) during the third quarter, according to its most recent filing with the SEC. The fund purchased 382,840 shares of the company's stock, valued at approximately $1,405,000. Jacobs Levy Equity MDecember 9, 2024 | marketbeat.comPyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts AheadDecember 7, 2024 | seekingalpha.comCFO & COO of Pyxis Oncology Pamela Connealy Buys 13% More SharesDecember 1, 2024 | finance.yahoo.comPyxis Oncology, Inc. (NASDAQ:PYXS) CFO Pamela Ann Connealy Purchases 88,850 SharesNovember 28, 2024 | insidertrades.comPyxis Oncology's SWOT analysis: ADC innovator's stock poised for growthNovember 27, 2024 | uk.investing.comInstitutional owners may ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) recent US$142m market cap decline as longer-term profits stay in the greenNovember 27, 2024 | finance.yahoo.comRBC ups Pyxis Oncology target, says buy shares on selloffNovember 23, 2024 | markets.businessinsider.comStifel Nicolaus Remains a Buy on Pyxis Oncology (PYXS)November 23, 2024 | markets.businessinsider.comPyxis Oncology downgraded to Market Perform from Outperform at William BlairNovember 22, 2024 | markets.businessinsider.comPyxis Oncology reported ‘compelling’ cancer dataset, says H.C. WainwrightNovember 22, 2024 | markets.businessinsider.comWilliam Blair Downgrades Pyxis Oncology (PYXS)November 22, 2024 | msn.comPyxis stock craters 46% amid Phase 1 data, William Blair downgradeNovember 22, 2024 | msn.comPyxis Oncology's Cancer Drug Progress Stirs Analyst ConcernsNovember 21, 2024 | benzinga.comHC Wainwright Reaffirms Buy Rating for Pyxis Oncology (NASDAQ:PYXS)HC Wainwright restated a "buy" rating and set a $7.00 price target on shares of Pyxis Oncology in a report on Thursday.November 21, 2024 | marketbeat.comPyxis Oncology (NASDAQ:PYXS) Downgraded to "Market Perform" Rating by William BlairWilliam Blair cut Pyxis Oncology from an "outperform" rating to a "market perform" rating in a report on Thursday.November 21, 2024 | marketbeat.comPyxis Oncology Reports Promising Phase 1 Trial ResultsNovember 21, 2024 | markets.businessinsider.comPyxis Oncology announces preliminary PYX-201 data, collaboration with MerckNovember 20, 2024 | markets.businessinsider.comPyxis Oncology plummets 38% on preliminary phase 1 data for cancer assetNovember 20, 2024 | msn.comPyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 DataNovember 20, 2024 | globenewswire.comPyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been given an average rating of "Buy" by the eight brokerages that are presently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy rating. The average 1 year price objecNovember 18, 2024 | marketbeat.comPyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Up 19.3% in OctoberPyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 5,860,000 shares, a growth of 19.3% from the October 15th total of 4,910,000 shares. Based on an average daily volume of 504,200 shares, the short-interest ratio is presently 11.6 days. Currently, 13.3% of the company's stock are sold short.November 17, 2024 | marketbeat.comFY2024 EPS Estimate for Pyxis Oncology Decreased by AnalystPyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - HC Wainwright cut their FY2024 earnings per share (EPS) estimates for Pyxis Oncology in a report issued on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($1.00) per share for the yNovember 15, 2024 | marketbeat.comBrokers Set Expectations for Pyxis Oncology FY2024 EarningsPyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - William Blair cut their FY2024 earnings per share estimates for Pyxis Oncology in a research note issued to investors on Tuesday, November 12th. William Blair analyst A. Hsieh now anticipates that the company will post earnings per share of ($1.0November 15, 2024 | marketbeat.comPromising Prospects for Pyxis Oncology Amidst Strong Financial Position and Innovative Cancer TherapiesNovember 14, 2024 | markets.businessinsider.comPositive Outlook on Pyxis Oncology: Jeffrey La Rosa’s Buy Rating Driven by Anticipated Phase 1 Data for PYX-201November 14, 2024 | markets.businessinsider.comPositive Outlook for Pyxis Oncology: Strong Clinical Programs and Financial Stability Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comPyxis Oncology to host investor event to present preliminary PYX-201 dataNovember 12, 2024 | markets.businessinsider.comPyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024November 12, 2024 | markets.businessinsider.comStephens & Co. Initiates Coverage of Pyxis Oncology (PYXS) with Overweight RecommendationNovember 9, 2024 | msn.comPyxis Oncology initiated with an Overweight at StephensNovember 8, 2024 | markets.businessinsider.comPyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% UpsideNovember 8, 2024 | benzinga.comStephens Begins Coverage on Pyxis Oncology (NASDAQ:PYXS)Stephens began coverage on Pyxis Oncology in a report on Friday. They issued an "overweight" rating and a $13.00 price target for the company.November 8, 2024 | marketbeat.comabrdn plc Acquires 204,742 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS)abrdn plc lifted its holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) by 28.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 913,045 shares of the company's stock aftNovember 4, 2024 | marketbeat.comPyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Buy" from AnalystsPyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has received an average recommendation of "Buy" from the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy recommendation. The average 1-year target price among bOctober 24, 2024 | marketbeat.comLeerink Partnrs Lowers Earnings Estimates for Pyxis OncologyPyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Analysts at Leerink Partnrs dropped their Q3 2024 earnings per share (EPS) estimates for Pyxis Oncology in a research note issued to investors on Tuesday, October 15th. Leerink Partnrs analyst J. La. Rosa now expects that the company will earn ($October 18, 2024 | marketbeat.comOptimistic Buy Recommendation for Pyxis Oncology: Promising Prospects for Lead Drug PYX-201October 17, 2024 | markets.businessinsider.comMillennium Management LLC Grows Stock Holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS)Millennium Management LLC increased its holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) by 125.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,336,908 shares of the company's stock after purchasOctober 13, 2024 | marketbeat.com Get Pyxis Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter. Email Address PYXS Media Mentions By Week PYXS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PYXS News Sentiment▼0.000.60▲Average Medical News Sentiment PYXS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PYXS Articles This Week▼02▲PYXS Articles Average Week Get Pyxis Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CRVS News TRVI News CMPS News AQST News GOSS News CADL News ATYR News IMMP News OLMA News KRRO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PYXS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pyxis Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
